⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TELO News
Telomir Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
TELO
Form 8-K
sec.gov
TELO
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
accessnewswire.com
TELO
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
accessnewswire.com
TELO
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
accessnewswire.com
TELO
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
accessnewswire.com
TELO
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
accessnewswire.com
TELO
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
accessnewswire.com
TELO
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
accessnewswire.com
TELO
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
accessnewswire.com
TELO
TELO